Deutsche Biotech Innovativ AG (VUA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Deutsche Biotech Innovativ AG (VUA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8197
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Deutsche Biotech Innovativ AG (DBI), formerly Venetus Beteiligungen AG, is a biotechnology company that develops drug candidates on indications sepsis and cancer. The company’s products comprise Adrecizumab, DB1RA and AB2302. It diagnostic based drug development approach and offers identification of relevant biomarkers in the blood such as endogenous molecules and develops diagnostic assays. DBI develops therapies to prevent septic shock and inhibit tumor growth. The company develops Adrecizumab, a monoclonal adrenomedullin-specific antibody, which is in Phase II clinical trial as a therapy against septic shock to reduce sepsis mortality. It also offers small molecule drugs for breast cancer prevention. It also invests in research and drug development programs. Deutsche Biotech is headquartered in Hennigsdorf, Germany.

Deutsche Biotech Innovativ AG (VUA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Deutsche Biotech Innovativ Raises USD0.2 Million in Public Offering of Shares 10
Deutsche Biotech Innovativ to Raise USD0.2 Million in Private Placement of Shares 11
Deutsche Biotech Innovativ Raises USD2 Million in Private Placement of Shares 12
Deutsche Biotech Plans to Raise funds through Rights Offering of Shares 13
Acquisition 14
Deutsche Biotech Innovativ Acquires AngioBiomed 14
Deutsche Biotech Innovativ Acquires 25% Stake in Oncoprevent 15
Deutsche Biotech Innovativ AG – Key Competitors 16
Deutsche Biotech Innovativ AG – Key Employees 17
Deutsche Biotech Innovativ AG – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Deutsche Biotech Innovativ AG, Deals By Therapy Area, 2012 to YTD 2018 8
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Deutsche Biotech Innovativ Raises USD0.2 Million in Public Offering of Shares 10
Deutsche Biotech Innovativ to Raise USD0.2 Million in Private Placement of Shares 11
Deutsche Biotech Innovativ Raises USD2 Million in Private Placement of Shares 12
Deutsche Biotech Plans to Raise funds through Rights Offering of Shares 13
Deutsche Biotech Innovativ Acquires AngioBiomed 14
Deutsche Biotech Innovativ Acquires 25% Stake in Oncoprevent 15
Deutsche Biotech Innovativ AG, Key Competitors 16
Deutsche Biotech Innovativ AG, Key Employees 17
Deutsche Biotech Innovativ AG, Subsidiaries 18

List of Figures
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Deutsche Biotech Innovativ AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Deutsche Biotech Innovativ AG (VUA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CareDx Inc (CDNA):企業の財務・戦略的SWOT分析
    Summary CareDx Inc (CareDx) formerly XDx Inc, is a molecular diagnostics company focused on the discovery, development, and commercialization of diagnostic solutions for transplant patients. The company offers products which include AlloMap, a noninvasive blood test used by clinicians to monitor and …
  • Cleveland HeartLab Inc-医療機器分野:企業M&A・提携分析
    Summary Cleveland HeartLab Inc (Cleveland HeartLab) is a clinical laboratory that provides cardiovascular testing services. The company offers services such as cardiovascular risk assessment, novel diagnostic tests, inflammatory and other advanced biomarker testing, management and prevention of hear …
  • Asos Plc:企業の戦略・SWOT・財務分析
    Asos Plc - Strategy, SWOT and Corporate Finance Report Summary Asos Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • EPI Ingredients:企業の戦略・SWOT・財務分析
    EPI Ingredients - Strategy, SWOT and Corporate Finance Report Summary EPI Ingredients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Motorola Solutions Inc (MSI):企業の財務・戦略的SWOT分析
    Motorola Solutions Inc (MSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Elong Inc:企業の戦略・SWOT・財務分析
    Elong Inc - Strategy, SWOT and Corporate Finance Report Summary Elong Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Ethiopian Electric Power Corp:電力:M&Aディール及び事業提携情報
    Summary Ethiopian Electric Power Corp (Ethiopian Electric Power), formerly The Ethiopian Electric Light and Power Authority, is an electric utility that generates, transmits and distributes electricity. The utility maintains the Interconnected System and transmits electricity from hydropower plants …
  • Promedior Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Promedior Inc (Promedior) is a clinical-stage biotechnology company that develops medicines for the treatment of fibrotic disorders. The company’s pipeline products include PRM-151 and PRM-167. PRM-151 is used in the treatment of rare systemic fibrotic diseases such as myelofibrosis and idio …
  • Senex Energy Ltd (SXY):石油・ガス:M&Aディール及び事業提携情報
    Summary Senex Energy Ltd (Senex), formerly Victoria Petroleum NL, is an independent upstream oil and gas exploration and production company that acquires, explores and develops oil and gas assets in the Surat Basin and the Cooper Basin. The company extracts natural gas from coal seams. Its oil and g …
  • TOTAL S.A.:企業のM&A・事業提携・投資動向
    TOTAL S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TOTAL S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Living Cell Technologies Ltd (LCT):企業の財務・戦略的SWOT分析
    Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • OneMain Holdings Inc:企業の戦略・SWOT・財務分析
    OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Okamoto Industries, Inc.
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ethicon US LLC:医療機器:M&Aディール及び事業提携情報
    Summary Ethicon US LLC (Ethicon), a subsidiary of Johnson and Johnson, is a medical equipment company which operates through Ethicon Inc, and Ethicon Endo-Surgery Inc. It develops and markets surgical instruments and devices. Its major products include staplers, energy devices, clip appliers, trocar …
  • Statkraft AS:企業の戦略・SWOT・財務分析
    Statkraft AS - Strategy, SWOT and Corporate Finance Report Summary Statkraft AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Manchester United Plc:企業の戦略・SWOT・財務情報
    Manchester United Plc - Strategy, SWOT and Corporate Finance Report Summary Manchester United Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Texas Health Resources:企業の戦略的SWOT分析
    Texas Health Resources - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mithra Pharmaceuticals SA (MITRA):企業の財務・戦略的SWOT分析
    Summary Mithra Pharmaceuticals SA (Mithra) develops and manufactures over the counter products for women’s health and other applications. The company offers various drug products such as donesta, estelle, tibelia, myring, and zoreline. Its products are used in the treatment of contraception and fert …
  • ANGLE Plc (AGL):製薬・医療:M&Aディール及び事業提携情報
    Summary ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of …
  • Carisma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carisma Therapeutics Inc (Carisma Therapeutics), formerly CARMA Therapeutics LLC, is a biotechnology company with focus on the discovery and development of macrophage-based immunotherapeutics for the treatment of cancer. The company exploits its proprietary CAR-macrophage platform to provide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆